Alameda

Electronic Transaction Consultants signs contract with Alameda CTC for Electronic Toll System Integration

Retrieved on: 
Tuesday, December 13, 2022
International Road Dynamics, Maintenance, Congestion, Coronavirus, Perception, ETC, Transport, Big data, Alameda, ALPR, Risk, Partnership, Intellectual property, Software as a service, Intelligent transportation system, Disease, Commission, COVID-19, News, TSX, Machine learning, IRD, Acquisition, ITS, AET, Algorithm, Renewable energy, Risk management

TORONTO, Dec. 13, 2022 /PRNewswire/ - Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF) announces that the Alameda County Transportation Commission (Alameda CTC) has signed a contract with Electronic Transaction Consultants, LLC (ETC), a Quarterhill company, for the implementation and operation of the electronic toll system integration services for the I-680 Express Lanes.

Key Points: 
  • TORONTO, Dec. 13, 2022 /PRNewswire/ - Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF) announces that the Alameda County Transportation Commission (Alameda CTC) has signed a contract with Electronic Transaction Consultants, LLC (ETC), a Quarterhill company, for the implementation and operation of the electronic toll system integration services for the I-680 Express Lanes.
  • Alameda CTC is the managing agency for the I-680 Express Lanes on behalf of the I-680 Sunol Smart Carpool Lane Joint Powers Authority.
  • Over the course of the contract, ETC will deliver a new toll system for the I-680 Express Lanes, implementing ETC's next-generation express lane toll management system to improve mobility and alleviate congestion along the corridor.
  • The Alameda County Transportation Commission (Alameda CTC) coordinates countywide transportation planning and delivers essential, voter-supported transportation improvements in every city throughout Alameda County.

WNDR Alpine Unveils the All-New Intention 108 Backcountry Ski with SpiralMade™ Material Developed from Reclaimed Manufacturing Waste and Designed for Performance

Retrieved on: 
Monday, July 18, 2022
Skiing, Snowboarding, Sports, Outdoors, General Sports, Recycling, Consumer, Environment, Other Manufacturing, Other Consumer, Engineering, Chemicals, Plastics, Manufacturing, Alpine, Athlete, WNDR, Torque, Textile, Alameda, Vital, Intention, Polyurethane, Recycling, Skiing, Multimedia, Product innovation, CA, Marketing, Â, Spiral, Partnership, GM, Microalgae, VP, Reason, 3D printing, Melitaeini, Winter sports

View the full release here: https://www.businesswire.com/news/home/20220718005077/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220718005077/en/
    WNDR Alpine's Spiral Plate binding mounting plate improves retention strength while diverting waste from the landfill.
  • As a result, it was time to rethink the Intention to hone in on the areas where we believe a medium waist width backcountry ski should truly excel.
  • Debuting in WNDR Alpines new lineup are SpiralMade materials - embodied by a reuse of production waste developed in-house by WNDR Alpines team of designers, engineers, and materials scientists.
  • Checkerspot's first commercialized materials are next generation polyurethanes and textile finishes designed to improve the performance of consumer products.

Stand Forward, Stand Sideways, Stand for Something: WNDR® Alpine Launches First Snowboards, the BelleTour and the BelleAire

Retrieved on: 
Monday, July 11, 2022
Sports, General Sports, Manufacturing, Men, Green Technology, Environment, Engineering, Consumer, Skiing, Snowboarding, Sustainability, Chemicals, Plastics, Partnership, Winter, Microalgae, CA, Industry, Nature, Pacific Northwest, Alameda, Alpine, Goal, Snow, Polyurethane, Multimedia, Technology, Belleair, Florida, WNDR, Eastern Sierra, VP, Season, Veteran, Textile, Risk management, Winter sports, Melitaeini

WNDR Alpine the outdoor brand launched by advanced materials company Checkerspot is officially releasing its first two snowboards: the BelleTour splitboard and the BelleAire solid.

Key Points: 
  • WNDR Alpine the outdoor brand launched by advanced materials company Checkerspot is officially releasing its first two snowboards: the BelleTour splitboard and the BelleAire solid.
  • The BelleTour and the BelleAire are the first snowboards on the market featuring the award winning brands AlgalTech materials derived from microalgae oil.
  • View the full release here: https://www.businesswire.com/news/home/20220711005258/en/
    The all-new BelleTour splitboard and BelleAire solid.
  • In addition, the boards feature WNDR Alpines all-new SpiralMade materials, in the form of Spiral Plate binding insert packs.

Will & Co. Announces Strategic Collaboration to Bring Checkerspot’s Novel Biobased Materials and Algal Polyurethane Systems to European Product Innovators

Retrieved on: 
Tuesday, June 7, 2022
Engineering, Chemicals, Plastics, Other Manufacturing, Manufacturing, Will, CA, Textile, Microalgae, Climate change, Business, Partnership, Multimedia, Co-processing, Alpine, Industry, Alameda, Carbon, Paint, Melitaeini

Through this collaboration, Will & Co. and Checkerspot will work together to provide European partners with high performance polyurethane systems with high biocontent and attractive sustainability profiles.

Key Points: 
  • Through this collaboration, Will & Co. and Checkerspot will work together to provide European partners with high performance polyurethane systems with high biocontent and attractive sustainability profiles.
  • View the full release here: https://www.businesswire.com/news/home/20220607005235/en/
    Checkerspot's pure algae oil is the base for the high performing, high biocontent, polyurethane systems.
  • The ability to design for performance is a key benefit of working with these new materials.
  • Checkerspot's first commercialized materials are next generation polyurethane and textile finishes designed to improve the performance of consumer products.

Alameda Research invests into Klaytn's vision of the metaverse

Retrieved on: 
Thursday, April 21, 2022
Partner, FTX, Krust, Alameda, Kakao, Growth, US, Ecosystem, Investment, Partnership, Research, Cryptocurrency, Renewable energy

SINGAPORE, April 21, 2022 /PRNewswire/ --Klaytn Foundation, a dominant metaverse blockchain ecosystem backed by internet giant Kakao Corp, has announced the onboarding of Alameda Research as a strategic partner and investor into the Klaytn blockchain ecosystem.

Key Points: 
  • SINGAPORE, April 21, 2022 /PRNewswire/ --Klaytn Foundation, a dominant metaverse blockchain ecosystem backed by internet giant Kakao Corp, has announced the onboarding of Alameda Research as a strategic partner and investor into the Klaytn blockchain ecosystem.
  • "Having seen the immense potential of the Klaytn ecosystem, we're excited to be a part of the journey on Klaytn's roadmap for the metaverse.
  • We look forward to contributing to its future developments and success," shared Brian Lee, Partner of Alameda Research Ventures.
  • The extension of the partnership will mean greater involvement by Alameda Research to support the growth and development of the Klaytn ecosystem.

The Luxury Collection Announces New Global Explorer Caroline de Maigret

Retrieved on: 
Tuesday, December 14, 2021
Instagram, The Ritz-Carlton Hotel Company, Travel, W Hotels, Catedral, Exhibition, Chamber, NASDAQ, Jules Maigret, Assouline Publishing, Alameda, Global Explorer ROV, Seville Cathedral, Collection, Lunch, Hotel Alfonso XIII, Program, Multimedia, Duke, Twitter, CIGA, Luxury, Rihanna, Heart, View, Hotel, Facebook, Marriott International

NEW YORK, Dec. 14, 2021 /PRNewswire/ --The Luxury Collection, part of Marriott Bonvoy's portfolio of 30 extraordinary hotel brands,announces Caroline de Maigret as the brand's newest Global Explorer.

Key Points: 
  • NEW YORK, Dec. 14, 2021 /PRNewswire/ --The Luxury Collection, part of Marriott Bonvoy's portfolio of 30 extraordinary hotel brands,announces Caroline de Maigret as the brand's newest Global Explorer.
  • The Luxury Collection's Global Explorer program celebrates the vibrancy of the world's most enchanting destinations through the eyes of leading cultural voices.
  • Caroline de Maigret will join the celebrated group of Luxury Collection Global Ambassadors who bring the portfolio to life for international travelers.
  • For the global explorer, The Luxury Collection offers a gateway to the world's most exciting and desirable destinations.

Spotlight Poster Presentation at San Antonio Breast Cancer Symposium SABCS 2021 Shows Oncocyte’s DetermaIO™ Clinical Test Predicts Response to Immunotherapy in Triple Negative Breast Cancer

Retrieved on: 
Thursday, December 9, 2021
U.S. Securities and Exchange Commission, Physician, Biomarker, PCR, TNBC, Company, IO, RT, Neoplasm, GLOBE, RNA-Seq, SEC, Immunotherapy, Technology, Therapy, NGS, West Pharmaceutical Services explosion, Forward-looking statement, ESMO, OCX, Failure, Immune system, Quality of life, Patient, Breast cancer, Lung, Cancer, Method, Accounting, MD, Certification, Maintenance, COVID-19, Adoption, Fondazione Child, Intellectual property, Survival, Goal, Diagnosis, Doctor of Philosophy, CLIA, Nasdaq, Tumor microenvironment, Gene expression, Medical imaging, Vaccine, Risk management

IRVINE, Calif., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer, today announced results showing the ability of the Company’s DetermaIO™ test, a commercially-available precision diagnostic designed to determine the likelihood of response to immunotherapies (IO), at the 2021 San Antonio Breast Cancer Symposium (SABCS 2021).

Key Points: 
  • The data also details the high-level concordance (92%) between the commercial test compared to the previously-reported NGS RUO (RNA-sequencing/RNA-Seq) version of the same test.
  • The comparison demonstrated the strikingly high reproducibility of the test regardless of where a sample is analyzed or what platform is used.
  • DetermaRx identifies early-stage lung cancer patients who are at high risk for cancer recurrence and who may benefit from adjuvant chemotherapy.
  • DetermaIO, a gene expression test currently used as a research-use only tool, assesses the tumor microenvironment to predict response to immunotherapies.

Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled Distribution of DetermaRx™ in China

Retrieved on: 
Wednesday, December 8, 2021
U.S. Securities and Exchange Commission, Physician, Forward-looking statement, Company, Neoplasm, Population, GLOBE, SEC, Technology, NGS, West Pharmaceutical Services explosion, OCX, Failure, Lung cancer, Patient, Industry, Technology transfer, Cancer, Accounting, Partnership, Certification, Incidence, Maintenance, COVID-19, RNA, Program, Intellectual property, Goal, Diagnosis, Nasdaq, NSCLC, Tumor microenvironment, CTO, Pharmaceutical industry

Per the agreement, Burning Rock has licensed Oncocytes proprietary risk stratification DetermaRx test in China, and is now poised to launch the test to the worlds largest early-stage lung cancer market.

Key Points: 
  • Per the agreement, Burning Rock has licensed Oncocytes proprietary risk stratification DetermaRx test in China, and is now poised to launch the test to the worlds largest early-stage lung cancer market.
  • Under the terms of the revised Exclusive Sublicense Agreement, Oncocyte has achieved part two of the three-part technology transfer, which enables Burning Rock to launch the DetermaRx risk stratification test commercially.
  • This part of the technology transfer included validation that DetermaRx test results achieved in Oncocytes diagnostic laboratory can be reproduced in Burning Rocks diagnostic laboratories.
  • The milestone payment to Oncocyte is subject to Burning Rock confirming completion of this final part of the technology transfer by April 30, 2022.

Oncocyte Corporation Hosting Business Update Call

Retrieved on: 
Monday, December 6, 2021
Patient, NSCLC, Review, TMB, Physiology, Forward-looking statement, Acquisition, Company, Large-cell lung carcinoma, Diagnosis, PCR, Cancer, Tumor microenvironment, Transplant, Kidney, Breast, West Pharmaceutical Services explosion, COVID-19, Goal, Eastern Time Zone, Biopsy, Physician, Intellectual property, Nasdaq, DNA, Neoplasm, GLOBE, Certification, OCX, Accounting, Polymerase, Maintenance, Immunosuppression, Failure, Liver, Dentistry, Medical imaging

The call will feature presentations from Oncocyte's management team who will provide an overall pipeline update and an overview of the potential of DetermaIO to predict the response to immuno-oncology therapies.

Key Points: 
  • The call will feature presentations from Oncocyte's management team who will provide an overall pipeline update and an overview of the potential of DetermaIO to predict the response to immuno-oncology therapies.
  • Additionally, management will present plans for entering the transplant market with Oncocytes TheraSure Transplant Monitor test, which Oncocyte expects to market as DetermaCNITM in the United States.
  • This allows treatment of acute rejection and other causes of graft injury, potentially improving organ transplant outcomes in patients significantly.
  • The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives by accelerating the diagnosis of cancer and advancing cancer care.

Jitterbit Names Jill Ransome Chief Marketing Officer

Retrieved on: 
Thursday, December 2, 2021
API, CEO, Software as a service, Apollo Global Management, Female, Twitter, GLOBE, Marketing, Organization, CMO, LinkedIn, Growth, Intelligence, Sales

ALAMEDA, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Jitterbit, the API transformation company, today announced it has named Jill Ransome its new Chief Marketing Officer, the company’s first female CMO. Bringing more than 24 years of marketing, brand development and sales management experience to the role, Ransome will lead marketing efforts across the company, strengthening Jitterbit’s footprint with the acquisitions of eBridge Connections and Wevo to build a unified, global brand.

Key Points: 
  • ALAMEDA, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Jitterbit ,the API transformation company, today announced it has named Jill Ransome its new Chief Marketing Officer, the companys first female CMO.
  • Bringing more than 24 years of marketing, brand development and sales management experience to the role, Ransome will lead marketing efforts across the company,strengthening Jitterbits footprint with the acquisitions of eBridge Connections and Wevo to build a unified, global brand.
  • Ransome joins from Tangoe, where she served as chief marketing officer for nearly three years.
  • Im thrilled to be joining Jitterbit at a time of such rapid growth, Ransome said.